Section Arrow
ORKA.NASDAQ
- Oruka Therapeutics Inc
Quotes are at least 15-min delayed:2026/11/04 16:03 EST
After Hours
Last
 --
-- (--)
Bid
100.89
Ask
101.12
High -- 
Low -- 
Volume -- 
Regular Hours (Closed)
Last
 100.64
+1.09 (+1.09%)
Day High 
102.515 
Prev. Close
99.55 
1-M High
101.41 
Volume 
517.63K 
Bid
100.89
Ask
101.12
Day Low
96.32 
Open
102.37 
1-M Low
70.5 
Market Cap 
6.59B 
Currency 美元 
P/E -- 
%Yield 67.21 
10-SMA 91.18 
20-SMA 84.27 
50-SMA 88.17 
52-W High 115.515 
52-W Low 25.23 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.04/-2.82
Enterprise Value
6.59B
Balance Sheet
Book Value Per Share
16.79
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
CRISCuris Inc.1.115+0.4011+56.18%0.2PE
After Hours -- -- --
KPTIKaryopharm Therapeutics Inc.0.0861-0.0022-2.49%-- 
After Hours -- -- --
GERNGeron Corp1.07+0.14+15.05%-- 
After Hours -- -- --
INOInovio Pharmaceuticals1.6005-0.0595-3.58%-- 
After Hours -- -- --
RXRXRecursion Pharmaceuticals3.87+0.19+5.16%-- 
After Hours -- -- --
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Oruka Therapeutics Inc a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its programs are to treat and potentially modify disease by targeting mechanisms with efficacy and safety involved in disease pathology and the activity of pathogenic tissue-resident memory T cells (TRMs). Its program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and otherconditions.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.